medigraphic.com
ISSN 1027-2852 (Digital)
ISSN 0864-4551 (Impreso)

2011, Número 1

<< Anterior Siguiente >>

Biotecnol Apl 2011; 28 (1)


Valor diagnóstico de la alfa-fetoproteína en el carcinoma hepatocelular

Hernández JC, Samada M, Roque A, Cruz Y, Howland I, Fernández I

Idioma: Ingles.
Referencias bibliográficas: 41
Paginas: 34-39
Archivo PDF: 169.05 Kb.


RESUMEN

El carcinoma hepatocelular (CHC) es la quinta y sexta neoplasia más frecuente en el mundo. En este trabajo se empleó la alfa-fetoproteína (AFP) por la técnica del sistema ultramicroanalítico (SUMA®), como marcador tumoral en 189 pacientes cirróticos evaluados en el Centro de Investigaciones Médico-Quirúrgicas (CIMEQ), entre enero de 1999 y septiembre de 2005. Los principales factores que se asociaron a una elevación de la AFP fueron el CHC y la cirrosis viral. Veintidós enfermos presentaron CHC (11.64%) y la causa más importante fue la cirrosis hepática viral, principalmente por el virus de la hepatitis C. Este marcador tumoral mostró una sensibilidad de 68.18% y una especificidad de 92.17%. Al combinarlo con la ecografía abdominal, se incrementó la sensibilidad a 86.36% y la especificidad a 100%. Se concluyó que la AFP tuvo valor en el diagnóstico del CHC.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.

  2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132:2557-76.

  3. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570-5.

  4. Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, et al. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer. 2008;8:200.

  5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36.

  6. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood). 2001;226:377-408.

  7. Ruoslahti E, Seppälä M. Studies of carcino-fetal proteins. 3. Development of a radioimmunoassay for alpha-fetoprotein. Demonstration of alpha-fetoprotein in serum of healthy human adults. Int J Canc. 1971;8:374-83.

  8. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747-53.

  9. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol. 2001;16:553-9.

  10. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273-8.

  11. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-30.

  12. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol. 2000;95:1535-8.

  13. Gad A, Tanaka E, Matsumoto A, El-Hamid Serwah A, Attia F, Hassan A, et al. Ethnicity affects the diagnostic validity of alpha-fetoprotein in hepatocellular carcinoma. As Pac J Clin Oncol. 2005;1:64-70.

  14. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Int Med. 2003;139:46-50.

  15. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002; 36:S84-92.

  16. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of a-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology. 2002;36: 410-7.

  17. Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR, et al. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology. 2000;47:1654-8.

  18. Daniele B, Bencivenga A, Megna AS,Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127 (5 Suppl 1):S108-12.

  19. Zinkin NT, Grall F, Bhaskar K, Out HH, Spentzos D, Kalmowitz B, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008;14(2):470-7.

  20. Huo TI, Hsia CI, Chu CJ, Huang YH, Lui WY, Wu JC, et al. The predictive ability of serum a-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance. J Surg Oncol. 2007;95:645-51.

  21. Schuppan D, Afdhal NH. Liver cirrosis. Lancet. 2008;371:838-51.

  22. Mandayam S, Jamal M, Morgan TR. Epidemiology of alcoholic liver disease. Sem Liver Dis. 2004;24(3):217-32.

  23. Marrero CR, Marrero JA. Viral hepatitis and hepatocellular carcinoma. Arch Med Res. 2007;38(6):612-20.

  24. Castañeda Guillot C. Hepatitis B crónica en la infancia. En: Hernández JC, Samada M (editores). Hepatología 2006. La Habana: Editorial CIMEQ; 2006. p. 231-43.

  25. Sherman M, Klein A. AASLD single-topic research conference on hepatocellular carcinoma: conference proceedings. Hepatology. 2004;40:1465-73.

  26. Wilson JF. Liver cancer on the rise. Ann Intern Med. 2005;142:1029-32.

  27. Seef LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006;25:3771-7.

  28. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110-8.

  29. Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: The demise of a brilliant star. Gastroenterology. 2009;137(1):26-9.

  30. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004;99(5):860-5.

  31. Tai WC, Hu TH, Wang JH, Hung CH, Lu SN, Changchien CS, et al. Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc. 2009;108(3):210-8.

  32. Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, Sullivan D, et al. Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C. J Viral Hepat. 2008;15:179-87.

  33. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23(10):1541-8.

  34. El-Houseini ME, Mohammed MS, Elshemey WM, Hussein TD, Desouky OS, Elsayed AA. Enhanced detection of hepatocellular carcinoma. Cancer Control. 2005;12(4):248-53.

  35. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000;95:1036-40.

  36. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995;22:432-8.

  37. Peng YC, Chan CS, Chen GH. The effectiveness of serum alphafetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepatogastroenterology. 1999;46:3208-11.

  38. Gómez Senent S, Gómez Raposo C, Segura Cabral JM. Guía para el diagnóstico, estadificación y tratamiento del hepatocarcinoma. Med Clin. 2007;128:741-8.

  39. Peterson MS, Baron RL. Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis. 2001;5:123-44.

  40. Tremolda F, Benevegnù L, Drago C, Casarin C, Cechetto A, Realdi G, et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by a-fetoprotein, ultrasound and fine-needle biopsy. Hepatogastroenterology. 1989;36:519-21.

  41. Kang JY, Lee TP, Yap I, Lun KC. Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers. J Gastroenterol Hepatol. 1992;7:463-8. 42. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications. Clin Chim Acta. 2008;395(1-2):19-26.




2020     |     www.medigraphic.com